Tag: a clinical-stage biotechnology company commercializing a novel vaccination platform
Vaxxas raises $34 million to clinically advance needle-free vaccines, including a next-generation COVID-19 vaccine...
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.
Featured Article
Australian Manufacturing Week 2026 to make Brisbane debut
Australia’s leading advanced manufacturing showcase, Australian Manufacturing Week (AMW), is set to return in 2026, marking its first-ever event in Brisbane.
